JP2019513761A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513761A5
JP2019513761A5 JP2018553102A JP2018553102A JP2019513761A5 JP 2019513761 A5 JP2019513761 A5 JP 2019513761A5 JP 2018553102 A JP2018553102 A JP 2018553102A JP 2018553102 A JP2018553102 A JP 2018553102A JP 2019513761 A5 JP2019513761 A5 JP 2019513761A5
Authority
JP
Japan
Prior art keywords
fibrosis
pharmaceutical composition
composition according
cholangitis
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018553102A
Other languages
English (en)
Japanese (ja)
Other versions
JP6894923B2 (ja
JP2019513761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/055878 external-priority patent/WO2017178172A1/en
Publication of JP2019513761A publication Critical patent/JP2019513761A/ja
Publication of JP2019513761A5 publication Critical patent/JP2019513761A5/ja
Application granted granted Critical
Publication of JP6894923B2 publication Critical patent/JP6894923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018553102A 2016-04-11 2017-03-13 胆汁うっ滞性及び線維性の疾患の処置方法 Active JP6894923B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11
EP16305425.7 2016-04-11
PCT/EP2017/055878 WO2017178172A1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (3)

Publication Number Publication Date
JP2019513761A JP2019513761A (ja) 2019-05-30
JP2019513761A5 true JP2019513761A5 (https=) 2020-03-26
JP6894923B2 JP6894923B2 (ja) 2021-06-30

Family

ID=55755536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018553102A Active JP6894923B2 (ja) 2016-04-11 2017-03-13 胆汁うっ滞性及び線維性の疾患の処置方法

Country Status (23)

Country Link
US (7) US20170290812A1 (https=)
EP (3) EP3777854B1 (https=)
JP (1) JP6894923B2 (https=)
KR (1) KR102431257B1 (https=)
CN (1) CN109069648B (https=)
AU (1) AU2017249602B2 (https=)
DK (2) DK3442580T3 (https=)
EA (2) EA202191466A1 (https=)
ES (3) ES2928408T3 (https=)
HR (1) HRP20201954T1 (https=)
HU (2) HUE052886T2 (https=)
IL (1) IL262052B (https=)
LT (1) LT3442580T (https=)
MD (1) MD3442580T2 (https=)
MX (1) MX384261B (https=)
MY (1) MY195437A (https=)
PH (1) PH12018502142B1 (https=)
PL (1) PL3442580T3 (https=)
PT (2) PT3777855T (https=)
SG (2) SG11201808402RA (https=)
SI (1) SI3442580T1 (https=)
WO (1) WO2017178172A1 (https=)
ZA (1) ZA201807389B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191466A1 (ru) 2016-04-11 2021-12-31 Женфит Способы лечения холестатических и фибротических заболеваний
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
KR20190122806A (ko) * 2017-03-13 2019-10-30 장피트 조합 치료요법용 약학 조성물
US11147779B2 (en) * 2017-03-21 2021-10-19 Supreet K. Deshpande Therapeutic agent for phosphodiesterase inhibition and its related disorders
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター,ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための[2-[(5-ニトロ-1,3-チアゾール-2-イル)カルバモイル]フェニル]エタノエート
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
CN113677336B (zh) 2019-04-10 2024-04-30 基恩菲特公司 包含式(i)化合物和glp-1受体激动剂的组合疗法
CA3130518A1 (en) * 2019-04-12 2020-10-15 Nicolas STANKOVIC-VALENTIN Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
CA3153784A1 (en) 2019-10-28 2021-05-06 Nicolas STANKOVIC-VALENTIN Combination therapy of elafibranor and nitazoxanide having antioxident properties
CN113398125B (zh) 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
CN116507343A (zh) * 2020-11-17 2023-07-28 基恩菲特公司 治疗肝衰竭的方法
CA3196479A1 (en) * 2020-11-17 2022-05-27 Philippe Delataille Methods of treatment of liver failure
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途
CN117241795A (zh) * 2021-05-11 2023-12-15 基恩菲特公司 治疗脓毒症的硝唑尼特
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用
WO2024074515A1 (en) * 2022-10-04 2024-04-11 Genfit Nitazoxanide for the treatment of hepatic impairment
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
WO2025063816A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물
CN117838690B (zh) * 2023-10-09 2024-09-13 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20100056505A1 (en) 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
AP2907A (en) * 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
CA2639910A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
EP2178852B9 (en) 2007-08-03 2016-06-22 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Clostridium propionicum 유래의프로피오닐―CoA 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
EP2203168B1 (en) 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
PE20121118A1 (es) 2009-05-12 2012-09-05 Romark Lab Lc Compuestos de haloalquil heteroaril benzamida
AP2012006064A0 (en) 2009-06-26 2012-02-29 Romark Lab Lc Compounds and methods for treating influenza.
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
AU2010319999B2 (en) 2009-11-16 2014-01-16 University Of Georgia Research Foundation, Inc. 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
CN103269593A (zh) 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
KR20190060879A (ko) 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
CN103648282B (zh) 2011-05-16 2017-02-15 罗马克实验室有限公司 噻唑化物类化合物用于预防和治疗病毒性疾病、癌症和由细胞内感染引起的疾病的用途
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
CN107105660A (zh) 2014-11-11 2017-08-29 罗马克实验室有限公司 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
US20190070154A1 (en) 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
CN109152760B (zh) 2016-04-11 2022-09-23 基恩菲特公司 胆汁淤积性和纤维化疾病的治疗方法
WO2017178174A1 (en) 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
EA202191466A1 (ru) 2016-04-11 2021-12-31 Женфит Способы лечения холестатических и фибротических заболеваний

Similar Documents

Publication Publication Date Title
JP2019513761A5 (https=)
D’Alessio et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study
HRP20201954T1 (hr) Metode liječenja kolestatskih i fibrotičnih bolesti
Esatoglu et al. Update on the treatment of Behçet’s syndrome
JP2019513762A5 (https=)
ES2768614T3 (es) Formulaciones de anticuerpos anti-PDL1
US20160146844A1 (en) Compositions and methods for binding lysophosphatidic acid
JP2017113019A5 (https=)
JP2007526208A (ja) 呼吸器の症状を治療又は予防する方法
JP2017515909A5 (https=)
JP2020535225A5 (https=)
JP2010500360A5 (https=)
Comeglio et al. Beneficial effects of bile acid receptor agonists in pulmonary disease models
Askanase et al. New and future therapies: changes in the therapeutic armamentarium for SLE
BR112018010337A2 (pt) anticorpo anti-alfa-v integrina para o tratamento de fibrose e/ou transtornos fibróticos
JP2017141225A5 (https=)
Bou et al. Treatment of uveitis associated with juvenile idiopathic arthritis
RU2017122758A (ru) Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций
JP2013028611A5 (https=)
TW200812589A (en) Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
Williams et al. The biased apelin receptor agonist, MM07, reverses Sugen/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan
US20100247538A1 (en) IL-18 and Protein Kinase R Inhibition for the Treatment of COPD
JP2018524274A5 (https=)
US20060121043A1 (en) Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
Joshi et al. Lymphocytes contribute to biliary injury and fibrosis in experimental xenobiotic-induced cholestasis